Home Other Building Blocks 905579-51-3
905579-51-3,MFCD17215201
Catalog No.:AA00GU1O

905579-51-3 | MLN4924

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$42.00   $29.00
- +
5mg
≥98%
in stock  
$138.00   $96.00
- +
10mg
≥98%
in stock  
$240.00   $168.00
- +
25mg
95%
in stock  
$366.00   $257.00
- +
100mg
95%
in stock  
$954.00   $668.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00GU1O
Chemical Name:
MLN4924
CAS Number:
905579-51-3
Molecular Formula:
C21H25N5O4S
Molecular Weight:
443.5193
MDL Number:
MFCD17215201
SMILES:
O[C@H]1C[C@@H](C[C@H]1COS(=O)(=O)N)n1ccc2c1ncnc2N[C@H]1CCc2c1cccc2
Properties
Computed Properties
 
Complexity:
734  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
4  
Heavy Atom Count:
31  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
6  
XLogP3:
1.7  

Downstream Synthesis Route
905579-51-3   
CASUnavailable 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2007/191293,2007,A1Locationinpatent:Page/Pagecolumn53

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-US2007/191293,2007,A1Locationinpatent:Page/Pagecolumn53

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2010/132110,2010,A1Locationinpatent:Page/Pagecolumn37-38

[2]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2022/112951,2022,A1Locationinpatent:Paragraph0118;0119

((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo2,3-dpyrimidin-7-yl)-2-hydroxycyclopentyl)-methylsulfamate 
  1160295-21-5 

[1]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2010/132110,2010,A1Locationinpatent:Page/Pagecolumn38-39

[2]CurrentPatentAssignee:TAKEDAPHARMACEUTICALCOMPANYLIMITED-WO2022/112951,2022,A1Locationinpatent:Paragraph0120;0121

Literature

Title: Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.

Journal: eLife 20180101

Title: Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.

Journal: The Journal of biological chemistry 20150529

Title: The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20140315

Title: NEDD8 overexpression results in neddylation of ubiquitin substrates by the ubiquitin pathway.

Journal: Journal of molecular biology 20120803

Title: Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Journal: Pediatric blood & cancer 20120801

Title: The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.

Journal: Cancer research 20120701

Title: Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.

Journal: Molecular oncology 20120601

Title: A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.

Journal: Cell reports 20120419

Title: Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Journal: Cancer cell 20120320

Title: The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions.

Journal: Cell cycle (Georgetown, Tex.) 20120315

Title: Characterization of MRFAP1 turnover and interactions downstream of the NEDD8 pathway.

Journal: Molecular & cellular proteomics : MCP 20120301

Title: Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.

Journal: Molecular cancer research : MCR 20120301

Title: Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Journal: Cancer research 20120101

Title: The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.

Journal: PloS one 20120101

Title: The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.

Journal: Molecular cancer therapeutics 20111201

Title: Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.

Journal: Molecular & cellular proteomics : MCP 20111101

Title: Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20111101

Title: Global identification of modular cullin-RING ligase substrates.

Journal: Cell 20111014

Title: MLN4924 is an efficient inhibitor of NEDD8 conjugation in plants.

Journal: Plant physiology 20110601

Title: Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.

Journal: Neoplasia (New York, N.Y.) 20110601

Title: Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme.

Journal: The Journal of organic chemistry 20110506

Title: The steady-state repertoire of human SCF ubiquitin ligase complexes does not require ongoing Nedd8 conjugation.

Journal: Molecular & cellular proteomics : MCP 20110501

Title: Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.

Journal: Cancer research 20110415

Title: A natural product-like inhibitor of NEDD8-activating enzyme.

Journal: Chemical communications (Cambridge, England) 20110307

Title: Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid.

Journal: PloS one 20110101

Title: NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.

Journal: Cancer research 20101215

Title: Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.

Journal: Cell 20101210

Title: MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Journal: Blood 20100902

Title: Biochemical and cellular effects of inhibiting Nedd8 conjugation.

Journal: Biochemical and biophysical research communications 20100730

Title: Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Journal: Blood 20100506

Title: SUMO, Ubiquitin, UBL Proteins: Implications For Human Diseases - Fifth International Conference.

Journal: IDrugs : the investigational drugs journal 20100401

Title: Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Journal: Molecular cell 20100115

Title: Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Title: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Journal: Nature 20090409

Title: Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6.

Title: F S Wolenski, et al. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell Death Discovery 1, Article number: 15034 (2015)

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 905579-51-3
Tags:905579-51-3 Molecular Formula|905579-51-3 MDL|905579-51-3 SMILES|905579-51-3 MLN4924